Cancer treatment using platinum has vastly been associated with numerous side effects and resistance generation. As a result, current medicinal chemistry is now emphasized on the development of novel metal based drugs bearing diverse pharmacological profile. There has been an increasing interest in the drafting of Au(III) complexes as new metal based drugs. Au(III) complexes have been observed to be especially steady under different physicochemical situations. Dithiocarbamato-Au(III) complexes show antiproliferative property against specific human tumor cells because of their inhibiting effect towards the tumor cell augmentation. The review focuses on the results obtained in the field of anticancer and antimicrobial efficacy of Au(III) complexes. The represented Au(III) complexes as anticancer agents have been classified as (a) complexes containing Au-N bonds, (b) complexes containing Au-S bonds and (c) complexes containing Au-O bonds. Au(III) complexes as antimicrobial agents have been subdivided as (a) antibacterial and antifungal (b) antimalarial and (c) antitrypanosomial Au(III) complexes. The results obtained from the analysis of anticancer and antimicrobial Au(III) complexes could possibly lead to the design and development of novel potent Au(III) complexes exhibiting enhanced activities.
MaiaP.I.S., DeflonV.M. and AbramU., Gold(III) complexes in medicinal chemistry, Future Med Chem6(13) (2014), 1515–1536. doi:10.4155/fmc.14.87
3.
WilliamsM.L., Core chemistry of gold and its complexes, Inflammopharmacology16 (2008), 110–111. doi:10.1007/s10787-007-0019-4
4.
KeanW.F., ForestierF., KassamY., BuchananW.W. and RooneyP.J., The history of gold therapy in rheumatoid disease, Semin Arthritis Rheum14 (1985) 180–186. https://doi.org/10.1016/0049-0172(85)90037-X
5.
ZhaoH. and NingY., China’s ancient gold drugs, Gold Bull34 (2001), 24–29. doi:10.1007/BF03214805
6.
HigbyG.J., Gold in medicine, Gold Bull15(4) (1982), 130–140.
ShahZ.A. and VohoraS.B., Antioxidant/restorative effects of calcined gold preparations used in Indian systems of medicine against global and focal models of ischaemia, Pharmacol Toxicol90 (2002), 254–259. doi:10.1034/j.1600-0773.2002.900505.x
9.
KouodomM.N., BoscuttiG., CelegatoM., CrismaM., SitrandS., AldinucciD., FormaggioF., RonconiL. and FregonaD., Rational design of gold(III)-dithiocarbamato peptidomimetics for the targeted anticancer chemotherapy, J Inorg Biochem117 (2012), 248–260. doi:10.1016/j.jinorgbio.2012.07.001
10.
ChopraA.S., Ayurveda, H. SelinSpringer Science & Business Media: Norwell, 2003, pp. 74–111.
11.
SinghR.H. and MishraL.C., Psychiatric disorders, MishraL.C., Ed., Washington, DC, 2004, pp. 439–452.
12.
ChampionG.D., GrahamG.G. and ZieglarJ.B., The Gold complexes, Ballieres Clin Rheumatol4 (1990), 491–534.
GottliebN.L., Comparative pharmacokinetics of parenteral and oral gold compounds, J Rheumatol9 (1982), 99–109.
15.
SnyderR.M., MirabelliK. and CrookeS.T., The cellular pharmacology of auranofin, Semin Arthritis Rheum17 (1987), 71–80. doi:10.1016/0049-0172(87)90017-5
16.
HassanF., Abd alqadeem mohammedS.,
PhilipA.,
HameedA.A. and YousifE., Gold (III) complexes as breast cancer drug, Sys Rev Pharm8(1) (2017), 76–79. doi:10.5530/srp.2017.1.13
17.
SadlerP.J., The biological chemistry of gold: A Metallo-drug and heavy-atom label with variable valency, Struct Bonding29 (1976), 171–214. doi:10.1007/BFb0116521
18.
MaiaP., CarneiroZ.A., LopesC.D., OliveiraC.G., SilvaJ.S., AlbuquerqueS., HagenbachA., GustR., DeflondV.M. and AbramU., Organometallic gold(III) complexes with hybrid SNS-donating thiosemicarbazone ligands: Cytotoxicity and anti-trypanosoma cruzi activity, Dalton Trans46 (2017), 2559–2571. doi:10.1039/C6DT04307K
19.
ArivalaganK., RavichandranS., RangasamyS. and KarthikeyanE., Nanomaterials and its potential applications, Int J ChemTech Res3 (2011), 534–538. ISSN:0974-4290.
20.
KochR., An address on bacteriological research, Brit Med J2(1546) (1890), 380–383.
FrickerS.P., Medical use of gold compounds: Past, Present and Future, Gold Bull29 (1996), 53–60. doi:10.1007/BF03215464
23.
ForestierJ., Rheumatoid arthritis and its treatment by gold salts. The results of six years’ experience, Lab Clin Med20 (1935), 827–840.
24.
MilacicV., FregonaD. and DouQ.P., Gold complexes as prospective metal-based anticancer drugs, Histol Histopathol23 (2008), 101–108. ISSN: 0213-3911.
25.
BertrandB. and CasiniA., A golden future in medicinal inorganic chemistry: The promise of anticancer gold organometallic compounds, Dalton Trans43 (2014), 4209–4219. doi:10.1039/c3dt52524d
26.
GimenoM.C., The Chemistry of GoldLagunaA. Ed., John Wiley & Sons: Weinheim, Germany, 2008. doi:10.1002/9783527623778.ch1
27.
WangaX. and GuoZ., Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents, Dalton Trans12 (2008), 1521–1532. doi:10.1039/B715903J
28.
MarconG., CarottiS., CoronnelloM., MessoriL., MiniE., OrioliP., MazzeiT., CinelluM.A. and MinghettiG., Gold(III) Complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties, J Med Chem45(8) (2002), 1672–1677. doi:10.1021/jm010997w
29.
MassaiL., CirriD., MichelucciE., BartoliG., GuerriA., CinelluM.A., CoccoF., GabbianiC. and MessoriL., Organogold(III) compounds as experimental anticancer agents: Chemical and biological profiles, Biometals29 (2016), 863–872. doi:10.1007/s10534-016-9957-x
30.
BuckleyR.G., ElsomeA.M., FrickerS.P., HendersonG.R., TheobaldB.R.C., ParishR.V., HoweB.P. and KellandL.R., Antitumor properties of some 2-[(Dimethylamino)methyl]phenylgold(III) complexes, J Med Chem39 (1996), 5208–5214. doi:10.1021/jm9601563
31.
CharltonR.J., HarrisC.M., PatilH. and StephensonN.C., Five-coordinate gold(III) complexes of 2,2’-biquinolylInorg Nucl Chem Lett12 (1966) 409–414. https://doi.10.1016/S0020-1650(66)80008-9
32.
GlišićB.Ɖ. and DjuranM.I., Gold complexes as antimicrobial agents: An overview of different biological activities in relation to the oxidation state of the gold ion and the ligand structure, Dalton Trans43 (2014), 5951–5969. doi:10.1039/c4dt00022f
33.
WeinA.N., StockhausenA.T., HardcastleK.I., SaadeinM.R., PengB.S., WangD., ShinD.M., ChenG.Z. and EichlerJ.F., Tumor cytotoxicity of 5,6-dimethyl-1,10-phenanthroline and its corresponding gold(III) complex, J Inorg Biochem105 (2011), 663–668. doi:10.1016/j.jinorgbio.2011.01.006
34.
RonconiL., MarzanoC., ZanelloP., CorsiniM., MioloG., MaccaC., TrevisanA. and FregonaD., Gold(III) dithiocarbamate derivatives for the treatment of cancer: Solution chemistry, DNA binding, and hemolytic properties, J Med Chem49 (2006), 1648–1657. doi:10.1021/jm0509288
35.
DashK.C., SchmidbuarH., SigelH.E. and DekkerM., Gold complexes as Metallo drugs, Met Ions Biol Syst14 (1982), 179–205.
36.
Shaw IIIC.F., The biochemistry of gold, SchmidbaurH., Ed., John Wiley & Sons: Chichester, United Kingdom, 1999.
37.
SadlerP.J. and SueR.E., The chemistry of gold drugs, KepplerB.K., Ed., VCH Publ: Weinhein, 1994.
38.
KungK.K.Y., LoV.K.Y., KoH.M., LiG.L., ChanP.Y., LeungK.C., ZhouZ., WangM.Z., CheC.M. and WongaM.K., Cyclometallated Gold(III) complexes as effective catalysts for synthesis of propargylic amines, chiral allenes and isoxazoles, Adv Synth Catal355 (2013), 2055–2070. doi:10.1002/adsc.201300005
39.
LoV.K.Y., LiuY., WongM.K. and CheC.M., Gold(III) salen complex-catalyzed synthesis of propargylamines via a three-component coupling reaction, Org Lett8(8) (2006), 1529–153. doi:10.1021/ol0528641
40.
ZhouC.Y., ChanP.W.H. and CheC.M., Gold(III) porphyrin-catalyzed cycloisomerization of allenones, Org Lett8 (2006), 325–328. doi:10.1021/ol052696c
41.
HamdiM.Z. and MustafaI.A., Mixed ligand complexes of gold (III) with some amino acids and dithiocarbamates or dithiophosphates, Sci J Analyt Chem1 (2013), 21–27. doi:10.11648/j.sjac.20130102.13
42.
FreemanH.C., Metal complexes of amino acids and peptides, Eichhorn, Ed., Inorganic biochemistry. Elsevier: Amsterdam, 1973, pp. 121–166.
43.
HossainM.A., IslamM.S., AlamM.A. and SultanT., Synthesis, physiochemical studies and antimicrobial screening of metal complexes of Fe(III) and Au(III) with aminoacids, Int J Sci Tech Res2(7) (2013), 210–217.
44.
ManavN., MishraA.K. and KaushikN.K., In vitro antitumour and antibacterial studies of some Pt(IV) dithiocarbamate complexes, Spectrochim Acta6(1) (2006), 32–35. doi:10.1016/j.saa.2005.09.023
GreeneB., HoseaM. and Mc PhersonR., HenzlM.AlexanderM.D.DarnallD.W., Interaction of gold(I) and gold(III) complexes with algal biomass, Environ Sci Technol20 (1986), 627–632. doi:10.1021/es00148a014
47.
RajasekarK., RamachandramoorthyT. and PaulrajA., Microwave assisted synthesis, structural characterization and biological activities of 4-aminoantipyrine and thiocyanate mixed ligand complexes, Res J Pharmaceutical Sci1 (2012), 2–27. ISSN: 2319–555X.
48.
KauffmanG.B., The role of gold in alchemy: Part I, Gold Bull18(1) (1985), 31–44. doi:10.1007/BF03214684
49.
KauffmanG.B., The role of gold in alchemy: Part II, Gold Bull18(2) (1985), 69–78. doi:10.1007/BF03214689
50.
KauffmanG.B., The role of gold in alchemy: Part III, Gold Bull18(3) (1985), 109–119. doi:10.1007/BF03214693
ShawC.F., Gold complexes with anti-arthritic, anti-tumour and anti-HIV activity, FarrellN.P., Ed. Royal Society of Chemistry: Cambridge, UK, 1999, pp. 26–57. doi:10.1039/9781847552242-00026k
53.
SimonT.M., KunishimaD.H., VibertG.J. and LorberA., Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia, Cancer Res41 (1981), 94–97.
54.
BeckerK., GromerS., SchirmerR.H. and MüllerS., Thioredoxin reductase as pathophysiological factor and drug target, Eur J Biochem267 (2000), 6118–6125. doi:10.1046/j.1432-1327.2000.01703.x
55.
GromerS., ArscottL.D., WilliamsC.H., SchirmerR.H. and BeckerK., Human placenta thioredoxin reductase, J Biol Chem273 (1998), 20096–20101. doi:10.1074/jbc.273.32.20096
UrigS., Fritz-WolfK., ReauR., Herold-MendeC., TothK., Davioud-CharvetE. and BeckerK., Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases, Angew Chem Int Ed45 (2006), 1881–1886. doi:10.1002/anie.200502756
RosenbergB., CampL.V., TroskoJ.E. and MansourV.H., Platinum compounds: A new class of potent antitumour agents, Nature222 (1969), 385–386. doi:10.1038/222385a0
60.
O’DwyerP.J., StevensonJ.P., JohnsonS.W., Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, LiertB., Ed. John Wiley & Sons Inc: New York, 1999, pp. 31–72.
61.
WongE. and GiandomenicoC.M., Current status of platinum-based antitumor drugs, Chem Rev99 (1999), 2451–2466. doi:10.1021/cr980420v
62.
MessoriL., AbbateF., MarconG., OrioliP., FontaniM., MiniE., MazzeiT., CarottiS. and OȼConnellT., and ZanelloP.. Gold(III) complexes as potential antitumor agents: Solution chemistry and cytotoxic properties of some selected gold(III) compounds, J Med Chem43 (2000), 3541–3548. doi:10.1021/jm990492u
63.
BruijnincxP.C. and SadlerP.J., New trends for metal complexes with anticancer activity, Curr Opin Chem Biol12 (2008), 197–206. doi:10.1016/j.cbpa.2007.11.013
64.
JamiesonE.R. and LippardS.J., Structure, recognition and processing of cisplatin–DNA adducts, Chem Rev99 (1999), 2467–2498. doi:10.1021/cr980421n
65.
JungY. and LippardS.J., Direct cellular responses to platinum-induced DNA damage, Chem Rev107 (2007), 387–1407. doi:10.1021/cr068207j
66.
SadlerP.J. and SueR.E., The chemistry of gold drugs, Met Based Drugs1 (1994), 107–144. doi:10.1155/MBD.1994.107
67.
OttI., On the medicinal chemistry of gold complexes as anticancer drugs, Chem Rev253 (2009), 1670–1681. doi:10.1016/j.ccr.2009.02.019
68.
ZouT., LumC.T., LokC.N., ZhangJ.J. and CheC.M., Chemical biology of anticancer gold(III) and gold(I) complexes, Chem Soc Rev44 (2015), 8786–8801. doi:10.1039/C5CS00132C
69.
HickeyJ.L., RuhayelR.A., BarnardP.J., BakerM.V., Berners-PriceS.J. and FilipovskaA., Mitochondria-targeted chemotherapeutics: The rational design of gold(I)-Heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to Thiols, J Am Chem Soc130(38) (2008), 12570–12571. doi:10.1021/ja804027j
70.
ShiP., JiangQ., ZhaoY., ZhangY., LinJ., LinL., DingJ. and GuoZ., DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: The impact of steric and electrostatic effects, J Biol Inorg Chem11 (2006), 745–752. doi:10.1007/s00775-006-0120-y
71.
CinelluM.A., MaioreL., ManasseroM., CasiniA., ArcaM., FiebigH.H., KelterG., MichelucciE., PieracciniG. and GabbianiC., and MessoriL., [Au2(phen2Me)2(μ-O)2] a novel dinuclear gold(III) complex showing excellent antiproliferative propertiesACS Med Chem Lett1 (2010), 336–339. doi: 10.1021/ml100097f
72.
CheC.M., SunR.W.Y., YuW.Y., KoC.B., ZhuN. and SunH., Gold(III) porphyrins as a new class of anticancer drugs: Cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells, Chem Commun14 (2003), 1718–1719. doi:10.1039/b303294a
73.
ChowK.H.M.SunR.W.Y., LamJ.B.B., LiC.K., XuA., MaD.L., AbagyanR., WangY. and CheC.M., A Gold(III) Porphyrin Complex with Antitumor Properties Targets the Wnt/β-catenin Pathway, Cancer Res70 (2010), 329–337. http://dx.doi.org/10.1016/j.ica.2012.12.013
74.
LumC.T., SunR.W.Y., ZouT. and CheC.M., Synthesis of stable gold(III) pincer complexes with anionic heteroatom donors, Chem Sci5 (2014), 1579–1584. doi:10.1021/om500663m
75.
HeL., ChenT., YouY., HuH., ZhengW., KwongW.Y., ZouT. and CheC.M., A cancer-targeted nanosystem for delivery of gold(III) complexes: Enhanced selectivity and apoptosis-including efficacy of a gold(III) porphyrin complex, Angew Chem Int Ed53(46) (2014), 12532–12536. doi:10.1002/anie.201407143
76.
YanJ.J., ChowA.L.F., LeungC.H., SunR.W.Y., MaD.L. and CheC.M., Cyclometalated gold (III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons, Chem Commun46 (2010), 3893–3895. doi:10.1039/C2CC00029F
77.
ZhangJ.J., LuW., SunR.W.Y. and CheC.M., Organogold(III) supramolecular polymers for anticancer treatment, Angew Chem, Int Ed51 (2012), 4882–4886. doi:10.1002/anie.201108466
78.
ZouT., LumC.T., ChuiS.S.Y. and CheC.M., Gold(III) complexes containing N-Heterocyclic carbene ligands: Thiol “Switch-on” fluorescent probes and anti-cancer agents, Angew Chem, Int Ed52 (2013), 2930–2933. doi:10.1002/anie.201209787
79.
ZouT., LumC.T., LokC.N., ToW.P., LowK.H. and CheC.M., A binuclear gold(I) complex with mixed bridging diphosphine and bis(N-Heterocyclic carbene) ligands shows favorable thiol reactivity and inhibits tumor growth and angiogenesis in vivo, Angew Chem, Int Ed53 (2014), 5810–5814. doi:10.1002/anie.201400142
80.
TiekinkE.R.T., Anti-cancer potential of gold complexes, Inflammopharmacology16 (2008), 138–142. doi:10.1007/s10787-007-0018-5
81.
CalamaiP., CarottiS., GuerriA., MessoriL., MiniE., OrioliP. and SperoniG.P., Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm), J Inorg Biochem66 (1997), 103–109. doi:10.1016/S0162-0134(96)00190-0
82.
NobiliS., MiniE., LandiniI., GabbianiC., CasiniA. and MessoriL., Gold compounds as anticancer agents: Chemistry, cellular pharmacology, and preclinical studies, Med Res Rev30 (2010), 550–580. doi:10.1002/med.20168
83.
BindoliA., RigobelloM.P., ScutariG., GabbianiC., CasiniA. and MessoriL., Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs, Coord Chem Rev25 (2009), 1692–1707. doi:10.1016/j.ccr.2009.02.026
84.
GabbianiC., ScalettiF., MassaiL., MichelucciE., CinelluM.A. and MessoriL., Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: Biological and pharmacological implications, Chem Commun48(95) (2012), 11623–11625. doi:10.1039/c2cc36610j
85.
MartinsA.P., MarroneA., CiancettaA., CoboA.G., EchevarryaM., MouraT.F., ReN., CasiniA. and SoveralG., Targeting aquaporin function: Potent inhibition of aquaglyceroporin-3 by a gold-based compound, PLoS One7(5) (2012), e37435. doi:10.1371/journal.pone.0037435
86.
MartinsA.P., CiancettaA., AlmeidaA., MarroneA., ReN., SoveralG. and CasiniA., Aquaporin inhibition by gold(III) compounds: New insights, Chem Med Chem8(7) (2013), 1086–1092. doi:10.1002/cmdc.201300107
87.
TeoR.D., GrayH.B., LimP., TerminiJ., DomeshekE. and GrossZ., A cytotoxic and cytostatic gold(III) corrole, Chem Commun50 (2014), 13789–13792. doi:10.1039/C4CC06577H
88.
CasiniA., HartingerC., GabbianiC., MiniE., DysonP.J., KepplerB.K. and MessoriL., Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action, J Inorg Biochem102 (2008), 564–575. doi:10.1016/j.jinorgbio.2007.11.003
89.
RonconiL., GiovagniniL., MarzanoC., BettioF., GrazianiR., PilloniG. and FregonaD., Gold dithiocarbamate derivatives as potential antineoplastic agents: Design, spectroscopic properties, and in vitro antitumor activity, Inorg Chem44 (2005), 1867–1881. doi:10.1021/ic048260v
90.
GiovagniniL., RonconiL., AldinucciD., LorenzonD., SitranS. and FregonaD., Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosine dithiocarbamate complexes, J Med Chem48(5) (2005), 1588–1595. doi:10.1021/jm049191x
91.
MilacicV., ChenD., RonconiL., Landis-PiwowarK.R., FregonaD. and DouQ.P., A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenograft, Cancer Res66 (2006), 10478–10486. doi:10.1158/0008-5472.CAN-06-3017
92.
SaggioroD., RigobelloM.P., PaloschiL., FoldaA., MoggachS.A., ParsonsS., RoncoiniL., FregonaD. and BindoliA., Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway, Chem Biol14 (2007), 1128–1139. doi:10.1016/j.chembiol.2007.08.016
93.
FanD., LorenzonD., StefaniS.L., GiovagniniL., ColombattiA. and FregonaD., Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro, Anti-Cancer Drugs18 (2007), 323–332. doi:10.1097/CAD.0b013e328011ae98
94.
FanD., YangC.T., RanfordJ.D., VittalJ.J. and LeeP.F., Synthesis, characterization and biological activities of 2-phenylpyridine gold(III) complexes with thiolate ligands, Dalton Trans17 (2003), 3376–3381. doi:10.1039/ b307610e
95.
MessoriL., MarconG., CinelluM.A., CoronnelloM., MiniE. and GabbianiC., Solution chemistry and cytotoxic properties of novel organogold (III) compounds, Bioorg Med Chem12 (2004), 6039–6043. doi:10.1016/j.bmc.2004.09.014
96.
CoronnelloM., MiniE., CaciagliB., CinelluM.A., BindoliA., GabbianiC. and MessoriL., Mechanisms of cytotoxicity of selected organogold (III) compounds, J Med Chem48 (2005), 6761–6765. doi:10.1021/jm050493o
97.
BottenusB.N., KanP. and JenkinsT., Gold(III) bisthiosemicarbazonato complexes: Synthesis, characterization, radiochemistry and X-ray crystal structure analysis, Nucl Med Biol37 (2010), 41–49. doi:10.1016/j.nucmedbio.2009.08.003
98.
Nakajima, Accumulation of gold by microorganisms, World J Microb Biot19 (2003), 369–374. doi:10.1023/A:1023944905364
ParishR.V., HoweB.P., WrightJ.P., MackJ., PritchardR.G., BuckleyR.G., ElsomeA.M. and FrickerS.P., Chemical and biological studies of dichloro(2-((dimethylamino)methyl)phenyl)gold(III), Inorg Chem35 (1996), 1659–1666. doi:10.1021/ic950343b
ParishR.V., MackJ., HargreavesL., WrightJ.P., BuckleyR.G., ElsomeA.M., FrickerS.P. and TheobaldB.R.C., Chemical and biological reactions of diacetato[2-(dimethylaminomethyl)-phenyl]gold(III), [Au(O2CMe)2(dmamp)], J Chem Soc Dalton Trans1 (1996), 69–74. doi:10.1039/DT9960000069
103.
DingerM.B. and HendersonW., Organogold (III) metallacyclic chemistry. Part 4. Synthesis, characterisation and biological activity of gold(III)-thiosalicylate and salicylate complexes, J Organomet Chem560 (1998) 233–243. https://doi.org/10.1016/S0022-328X(98)00493-8
104.
DingerM.B. and HendersonW., Organogold(III) metallacyclic chemistry. Part 2. Synthesis and characterisation of the first gold(III) ureylene complexes, J Organomet Chem557 (1998) 231–241. https://doi.org/10.1016/S0022-328X(97)00712-2
105.
CariadoJ.J., Lopez-AriasJ.A., MaciasB., Femandez-LagoL.R. and SalasJ.M., Au(III) Complexes of tris-dithiocarbamate derivatives of alpha-amino-acids— spectroscopic studies, thermal-behavior and antibacterial activity, Inorg Chem Acta193 (1992), 229–235. doi:10.1016/S0020-1693(00)80357-6
106.
HemmertC., FabiéA., FabreA., Benoit-VicalF., GornitzkaH. and HemmertC., Synthesis, structures, and antimalarial activities of some silver(I), gold(I) and gold(III) complexes involving N-heterocyclic carbene ligands, Eur J Med Chem60 (2013), 64–75. doi:10.1016/j.ejmech.2012.11.038
107.
BiotC., CastroW., BottéC.Y. and NavarroM., The therapeutic potential of metal-based antimalarial agents: Implications for the mechanism of action, Dalton Trans41 (2010), 6335–6349. doi:10.1039/C2DT12225A
NavarroM., GabbianiC., MessoriL. and GambinoD., Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: Recent achievements and perspectives, Drug Discov Today15 (2010), 1070–1078. doi:10.1016/j.drudis.2010.10.005
110.
WasiN., SinghH.B., GajananaA. and RaichowdharyA.N., Synthesis of metal complexes of antimalarial drugs and in vitro evaluation of their activity against plasmodium falciparum, Inorg Chim Acta135 (1987), 133–137. https://doi.org/10.1016/S0020-1693(00)83277-6
111.
NavarroM., VásquezF., Sánchez-DelgadoR.A., PérezH., SinouV. and SchrévelJ., Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold–chloroquine complexes, J Med Chem47 (2004), 5204–5209. doi:10.1021/jm049792o
112.
GabbianiC., MessoriL., CinelluM.A., CasiniA., MuraP., SannellaA.R., SeveriniC., MajoriG., BiliaA.R. and VincieriF.F., Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials, J Inorg Biochem103 (2009), 310–312. doi:10.1016/j.jinorgbio.2008.10.004
113.
SannellaA.R., CasiniA., GabbianiC., MessoriL., BiliaA.R., VincieriF.F., MajoriG. and SeveriniC., New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications, FEBS Lett582 (2008), 844–847. doi:10.1016/j.febslet.2008.02.028
114.
KhanyeS.D., WanB., FranzblauS.G., GutJ., RosenthalP.J., SmithG.S., ChibaleK.C. and KhanyeS.D., Synthesis and in vitro antimalarial and antitubercular activity of gold(III) complexes containing thiosemicarbazone ligands, J Organomet Chem696 (2011), 3392–3396. doi:10.1016/j.jorganchem.2011.07.026
115.
SinghA. and RosenthalP.J., Comparison of efficacies of cysteine protease inhibitors against five strains of plasmodium falciparum, Antimicrob Agents Chemother45 (2001), 949–995. doi:10.1128/AAC.45.3.949-951.2001
116.
BrunR., BlumJ., ChappuisF. and BurriC., Human African trypanosomiasis, Lancet375 (2010), 148–159. doi:10.1016/S0140- 6736(09)60829-1
CavalliA. and BolognesiM.L., Neglected tropical diseases: Multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania, J Med Chem52 (2009), 7339–7359. doi:10.1021/jm9004835
119.
MoreiraD.R., LeiteA.C., SantosR.R.D. and SoaresM.B.P., Approaches for the development of new anti-trypanosoma cruzi agents, Curr Drug Targets10 (2009), 212–231. https://doi.org/10.2174/138945009787581140
120.
FrickerS.P., MosiR.M., CameronB.R., BairdI., ZhuY., AnastassovV., CoxJ., DoyleP.S., HansellE., LauG., LangilleJ., OlsenM., QinL., SkerljR., WongR.S., SantucciZ. and KerrowJ.H., Metal compounds for the treatment of parasitic diseases, J Inorg Biochem102 (2008), 1839–1845. doi:10.1016/j.jinorgbio.2008.05.010
121.
Sánchez-DelgadoR.A., NavarroM., LazardiK., AtencioR., CapparelliM., VargasF., UrbinaJ.A., BouillezA., NoelsA.F. and MasiD., Toward a novel metal based chemotherapy against tropical diseases 4. Synthesis and characterization of new metal-clotrimazole complexes and evaluation of their activity against Trypanosoma cruzi, Inorg Chim Acta275–276 (1998), 528–540. https://doi.org/10.1016/S0020-1693(98)00114-5
122.
NyarkoE., HaraT., GrabD.J., HabibA., KimY., NikolskaiaO., FukumaT. and TabataM., In vitro toxicity of palladium(II) and gold(III) porphyrins and their aqueous metal ion counterparts on Trypanosoma brucei brucei growth, Chem Biol Interact148 (2004), 19–25. doi:10.1016/j.cbi.2004.03.004
